Videos
Clinical Conversations by Experts
View all
Featured Videos
Analysis of Genomic Drivers of Discordant Risk Classifications in Prostate Cancer - Michael Zelefsky
Registry Data Shows Risk Migration With Blue Light Cystoscopy - Alireza Ghoreifi & Siamak Daneshmand
PIVOT-006: Phase III Trial of Creto vs Surveillance in Intermediate-Risk Bladder Cancer - Mark Tyson
PEACE-3 Trial Results Show Promise for Radium-223 and Enzalutamide in Asymptomatic mCRPC - Fred Saad
Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results - Yousef Zakharia
Access and Utilization of Healthcare by Adults with Spina Bifida - Lindsay Hampson & Alejandro Lopez
Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross
Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi
A Urologist's Perspective on PSMA-Radioligand Therapy in the Treatment Setting of mCRPC - Neal Shore
Management of pN1 Prostate Cancer (Including Systemic Therapy) APCCC 2022 Presentation - Derya Tilki
Access to Advanced Treatments in Landmark Advanced Prostate Cancer Clinical Trials - Bertrand Tombal
The Efficacy and Safety of Olaparib + Abiraterone in the First-Line mCRPC Setting PROpel – Fred Saad
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt
Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives
High-Risk Non-Muscle Invasive Bladder Cancer
Treatments in Development in NMIBC
Real-World Decision Making for Treating mHSPC: Case Discussions
Genomic Classifier in Prostate Cancer: Intermediate-Risk
Recent Conference Coverage
Conference Highlights Written by Physician Scientists
SNMMI 2026
- SNMMI 2026: Does Early 177Lu-PSMA-617 SPECT/CT Improve Prognostic Assessment Beyond Baseline PSMA PET in mCRPC?
- SNMMI 2026: Impact of External Beam Radiotherapy Use and Timing on Clinical Outcomes in Patients Receiving 177Lu-PSMA-617 + Best Standard of Care: A Secondary Analysis from the VISION Trial
- SNMMI 2026: Predictive Value of Baseline PSMA PET Imaging Biomarkers in 177Lu-DGUL Therapy: A Phase I/II trial Sub-analysis in mCRPC
ASCO 2026
- ASCO 2026: Prognostic Value of PSA Nadir and Meta-Analysis
- ASCO 2026: Clinical Outcomes with ERBB2 Gene Amplification and Activating Mutations in MIBC Patients Treated with Neoadjuvant Chemotherapy
- ASCO 2026: Ultrasensitive ctDNA Detection and Molecular Clearance as a Prognostic and Predictive Marker in Advanced RCC
Recent Physician-Scientist Review Articles
State of the Evidence Review Articles
Advanced Bladder Cancer
-
The Quickly Evolving Treatment Landscape of Metastatic Urothelial Carcinoma: A New Standard of Care in First-Line Systemic Therapy
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA and Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada
-
The Treatment Landscape of Metastatic Urothelial Carcinoma: Second-Line Systemic Therapy
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA and Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada
PSMA-Targeted Therapy
-
Beyond a VISION to Making a SPLASH: Advances in PSMA-Based Theranostics in Prostate Cancer
Written by Zachary Klaassen, MD, MSc, Medical College of Georgia, Augusta, Georgia
Transformative Evidence
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Trials in Progress
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information